Oncorus Inc. (NASDAQ:ONCR) shares traded -3.16% lower at $0.30 on Wall Street last session.
In accordance with the data, 4 analysts cover Oncorus Inc. (NASDAQ:ONCR). The consensus rating among analysts is ‘Overweight’. ONCR stock price is now -33.37% away from the 50-day moving average and -71.60% away from the 200-day moving average. The market capitalization of the company currently stands at $7.84M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 2 analysts and a buy by 2.
With the price target of $35, Maxim Group recently initiated with Buy rating for Oncorus Inc. (NASDAQ: ONCR). On October 27, 2020, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $40, while ‘Jefferies’ rates the stock as ‘Buy’.
In other news, Flynn James E, Possible Member of 10% Group sold 138,872 shares of the company’s stock on Dec 30. The stock was sold for $37,495 at an average price of $0.27. Upon completion of the transaction, the Possible Member of 10% Group now directly owns 284,697 shares in the company, valued at $85409.1. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 29, Possible Member of 10% Group Flynn James E sold 141,753 shares of the business’s stock. A total of $36,856 was realized by selling the stock at an average price of $0.26. This leaves the insider owning 299,917 shares of the company worth $89975.1. Insiders disposed of 87,170 shares of company stock worth roughly $26151.0 over the past 1 year. A total of 8.93% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ONCR stock. A new stake in Oncorus Inc. shares was purchased by AMALGAMATED FINANCIAL CORP. during the first quarter worth $1,000. In total, there are 73 active investors with 65.20% ownership of the company’s stock.
Oncorus Inc. (NASDAQ: ONCR) opened at $0.3100 on Thursday. During the past 12 months, Oncorus Inc. has had a low of $0.23 and a high of $4.68. As of last week, the company has a debt-to-equity ratio of 0.24, a current ratio of 5.00, and a quick ratio of 5.00. The fifty day moving average price for ONCR is $0.4505 and a two-hundred day moving average price translates $1.0570 for the stock.
The latest earnings results from Oncorus Inc. (NASDAQ: ONCR) was released for Jun, 2022.
Oncorus Inc.(ONCR) Company Profile
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company’s lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck’s cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
